DocGo (NASDAQ:DCGO) Price Target Cut to $6.50 by Analysts at Stifel Nicolaus

DocGo (NASDAQ:DCGO) had its price target lowered by Stifel Nicolaus from $8.00 to $6.50 in a research report report published on Tuesday, Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

A number of other brokerages have also recently commented on DCGO. Cantor Fitzgerald lowered their target price on DocGo from $13.00 to $11.00 and set an overweight rating for the company in a report on Thursday, February 29th. Canaccord Genuity Group dropped their price objective on shares of DocGo from $10.00 to $9.00 and set a buy rating for the company in a report on Thursday, April 11th. Needham & Company LLC reduced their target price on shares of DocGo from $14.00 to $10.00 and set a buy rating on the stock in a report on Thursday, February 29th. Finally, BTIG Research decreased their price target on shares of DocGo from $13.00 to $11.00 and set a buy rating for the company in a research report on Wednesday, April 10th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of Buy and an average price target of $10.58.

DocGo Stock Performance

Shares of DCGO stock opened at $3.38 on Tuesday. The firm has a market cap of $352.09 million, a P/E ratio of 48.29, a P/E/G ratio of 0.36 and a beta of 0.91. The firm’s 50 day moving average price is $3.70 and its 200-day moving average price is $4.51. DocGo has a one year low of $2.78 and a one year high of $10.82.

DocGo (NASDAQ:DCGO) last announced its earnings results on Wednesday, February 28th. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.07). DocGo had a net margin of 1.10% and a return on equity of 2.01%. The firm had revenue of $199.25 million during the quarter, compared to analysts’ expectations of $195.48 million. As a group, research analysts predict that DocGo will post 0.35 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Michael J. Burdiek acquired 10,000 shares of the company’s stock in a transaction on Thursday, March 14th. The shares were bought at an average cost of $3.61 per share, with a total value of $36,100.00. Following the transaction, the director now owns 571,595 shares in the company, valued at approximately $2,063,457.95. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. 13.78% of the stock is owned by insiders.

Institutional Trading of DocGo

A number of institutional investors have recently bought and sold shares of the business. AJOVista LLC purchased a new position in shares of DocGo in the 4th quarter valued at about $25,000. Victory Capital Management Inc. purchased a new position in DocGo in the third quarter valued at approximately $55,000. Cape Investment Advisory Inc. acquired a new stake in DocGo during the fourth quarter worth approximately $63,000. Envestnet Portfolio Solutions Inc. acquired a new stake in DocGo during the third quarter worth approximately $67,000. Finally, Intrust Bank NA purchased a new stake in shares of DocGo during the 4th quarter worth approximately $85,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

About DocGo

DocGo Inc provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services.